AMRZ vs STLD

The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.

STLD presents a dichotomy between strong growth fundamentals and stretched valuation metrics, anchored by a stable Piotroski F-Score of 4/9 and a missing Altman Z-Score. While the company exhibits impressive YoY earnings growth (34.7%) and a robust balance sheet (Current Ratio 3.06), the current price of $200.32 sits significantly above the Graham Number of $105.4. The extremely high PEG ratio of 11.95 and a bearish technical trend (10/100) suggest the stock is currently overextended despite its intrinsic growth value of $235.71. Consequently, the stock is viewed as a high-quality company trading at a premium price.